INNOVENT BIO 01801Hong Kong Stock Exchange

92.6500.05%( +0.050 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
INNOVENT BIO (01801) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2018-10-31
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG4818G1010
Southbound Connect
Shanghai · Shenzhen

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)15.29B15/112
Net Profit (Last FY)954.04M22/125
ROE (Last FY)4.20%46/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
De-Chao Michael Yu Executive Director
Qian Zhang Executive Director
Ronald Hao Xi Ede Non-Executive Director
Charles Leland Cooney Independent Non-Executive Director
Joyce I-Yin Hsu Independent Non-Executive Director
Gary Zieziula Independent Non-Executive Director
Shuyun Chen Independent Non-Executive Director
Stephen A. Sherwin Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-09-01.

About this page

This page shows INNOVENT BIO (01801) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.